CTIC - CTI BioPharma Corp.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.29
-0.02 (-0.60%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.31
Open3.30
Bid1.00 x 100
Ask3.35 x 2800
Day's Range3.29 - 3.38
52 Week Range0.36 - 6.48
Volume152,236
Avg. Volume170,818
Market Cap141.41M
Beta0.64
PE Ratio (TTM)-1.75
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube3 days ago

    ETFs with exposure to CTI BioPharma Corp. : October 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube17 days ago

    ETFs with exposure to CTI BioPharma Corp. : October 2, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
    Capital Cube20 days ago

    CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017

    Categories: Yahoo FinanceGet free summary analysis CTI BioPharma Corp. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 22.23 million, Net Earnings of USD 5.40 million. Gross margins widened from 96.40% to 98.80% compared to the same period last year, operating (EBITDA) margins now 33.57% from -256.17%. Change in operating ... Read more (Read more...)

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CTIC earnings conference call or presentation 3-Aug-17 8:30pm GMT

    Q2 2017 CTi Biopharma Corp Earnings Call

  • Associated Press3 months ago

    CTI BioPharma posts 2Q profit

    The Seattle-based company said it had profit of 3 cents per share. Earnings, adjusted for stock option expense, came to 6 cents per share. The biotechnology company posted revenue of $22.2 million in the ...

  • Capital Cube4 months ago

    ETFs with exposure to CTI BioPharma Corp. : June 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of CTIC earnings conference call or presentation 3-May-17 8:30pm GMT

    Q1 2017 CTi Biopharma Corp Earnings Call

  • CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017
    Capital Cube5 months ago

    CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017

    Categories: Yahoo FinanceGet free summary analysis CTI BioPharma Corp. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of CTI BioPharma Corp. – Novartis AG Sponsored ADR, Eli Lilly and Company, Amgen Inc., Bristol-Myers Squibb Company, Baxter International Inc., Incyte Corporation and Celgene Corporation (NVS-US, LLY-US, AMGN-US, ... Read more (Read more...)

  • Associated Press6 months ago

    CTI BioPharma reports 1Q loss

    On a per-share basis, the Seattle-based company said it had a loss of 71 cents. Losses, adjusted for stock option expense, came to 65 cents per share. The biotechnology company posted revenue of $754,000 ...

  • Capital Cube6 months ago

    ETFs with exposure to CTI BioPharma Corp. : April 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of CTIC earnings conference call or presentation 2-Mar-17 9:30pm GMT

    Q4 2016 CTi Biopharma Corp Earnings Call

  • Capital Cube7 months ago

    ETFs with exposure to CTI BioPharma Corp. : March 30, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017
    Capital Cube7 months ago

    CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017

    Categories: Yahoo Finance Get free summary analysis CTI BioPharma Corp. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of CTI BioPharma Corp. – Novartis AG Sponsored ADR, Eli Lilly and Company, Amgen Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Limited Sponsored ADR, Baxter International Inc., Incyte Corporation ... Read more (Read more...)

  • Associated Press8 months ago

    CTI BioPharma reports 4Q loss

    On a per-share basis, the Seattle-based company said it had a loss of 23 cents. Losses, adjusted for stock option expense, came to 16 cents per share. The biotechnology company posted revenue of $9.1 million ...

  • Why CTI BioPharma Corp. Stock Popped Today
    Motley Fool9 months ago

    Why CTI BioPharma Corp. Stock Popped Today

    The blood-cancer-focused biotech isn't out of the woods yet, but it looks like it will finally be allowed to continue an important clinical trial.

  • Capital Cube9 months ago

    ETFs with exposure to CTI BioPharma Corp. : January 4, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • CTI BioPharma Corp. breached its 50 day moving average in a Bullish Manner : CTIC-US : January 4, 2017
    Capital Cube9 months ago

    CTI BioPharma Corp. breached its 50 day moving average in a Bullish Manner : CTIC-US : January 4, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for CTI BioPharma Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Capital Cube10 months ago

    ETFs with exposure to CTI BioPharma Corp. : December 13, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Do Hedge Funds Love Manning and Napier Inc (MN)?
    Insider Monkey10 months ago

    Do Hedge Funds Love Manning and Napier Inc (MN)?

    Billionaire hedge fund managers such as Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the big players […]